Sifting through countless of stocks in the Biotechnology & Medical Research industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Immunocore Holdings PLC – ADR or ACADIA Pharmaceuticals Inc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Immunocore Holdings PLC – ADR and ACADIA Pharmaceuticals Inc compare based on key financial metrics to determine which better meets your investment needs.
About Immunocore Holdings PLC – ADR and ACADIA Pharmaceuticals Inc
Immunocore Holdings plc, formerly Immunocore Holdings Ltd, is a late-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies called Immune mobilizing monoclonal TCRs Against X disease (ImmTAX) designed to treat diseases, including cancer, infectious and autoimmune. The Company is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s pipeline is leveraging ImmTAX platform within three therapeutic areas: oncology, infectious disease and autoimmune disease. Its product candidate KIMMTRAK is used for positive adult patients with unresectable or metastatic uveal melanoma (mUM) having demonstrated in Phase III clinical trial.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and commercializes novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The Company’s pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The Company has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The Company also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).
Latest Biotechnology & Medical Research and Immunocore Holdings PLC – ADR, ACADIA Pharmaceuticals Inc Stock News
As of January 13, 2023, Immunocore Holdings PLC – ADR had a $2.8 billion market capitalization, compared to the Biotechnology & Medical Research median of $101.8 million. Immunocore Holdings PLC – ADR’s stock is NA in 2023, NA in the previous five trading days and up 131.06% in the past year.
Currently, Immunocore Holdings PLC – ADR does not have a price-earnings ratio. Immunocore Holdings PLC – ADR’s trailing 12-month revenue is $124.8 million with a -54.2% net profit margin. Year-over-year quarterly sales growth most recently was 598.3%. Analysts expect adjusted earnings to reach $-66.983 per share for the current fiscal year. Immunocore Holdings PLC – ADR does not currently pay a dividend.
Currently, ACADIA Pharmaceuticals Inc does not have a price-earnings ratio. ACADIA Pharmaceuticals Inc’s trailing 12-month revenue is $511.5 million with a -42.5% net profit margin. Year-over-year quarterly sales growth most recently was -0.7%. Analysts expect adjusted earnings to reach $-1.317 per share for the current fiscal year. ACADIA Pharmaceuticals Inc does not currently pay a dividend.
How We Compare Immunocore Holdings PLC – ADR and ACADIA Pharmaceuticals Inc Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Immunocore Holdings PLC – ADR and ACADIA Pharmaceuticals Inc’s stock grades to see how they measure up against one another.
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions